Vertex Pharmaceuticals Stock Price Prediction
| VRTX Stock | USD 464.56 2.51 0.54% |
Oversold Vs Overbought
55
Oversold | Overbought |
Quarterly Earnings Growth 0.01 | EPS Estimate Next Quarter 4.08 | EPS Estimate Current Year 0.5429 | EPS Estimate Next Year 18.7918 | Wall Street Target Price 514.805 |
Using Vertex Pharmaceuticals hype-based prediction, you can estimate the value of Vertex Pharmaceuticals from the perspective of Vertex Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors.
Vertex Pharmaceuticals Hype to Price Pattern
Investor biases related to Vertex Pharmaceuticals' public news can be used to forecast risks associated with an investment in Vertex. The trend in average sentiment can be used to explain how an investor holding Vertex can time the market purely based on public headlines and social activities around Vertex Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Vertex Pharmaceuticals' market sentiment to its price can help taders to make decisions based on the overall investors consensus about Vertex Pharmaceuticals.
The fear of missing out, i.e., FOMO, can cause potential investors in Vertex Pharmaceuticals to buy its stock at a price that has no basis in reality. In that case, they are not buying Vertex because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Vertex Pharmaceuticals after-hype prediction price | USD 463.38 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Vertex |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Vertex Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Vertex Pharmaceuticals After-Hype Price Prediction Density Analysis
As far as predicting the price of Vertex Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Vertex Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Vertex Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Vertex Pharmaceuticals Estimiated After-Hype Price Volatility
In the context of predicting Vertex Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Vertex Pharmaceuticals' historical news coverage. Vertex Pharmaceuticals' after-hype downside and upside margins for the prediction period are 461.64 and 465.12, respectively. We have considered Vertex Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Vertex Pharmaceuticals is very steady at this time. Analysis and calculation of next after-hype price of Vertex Pharmaceuticals is based on 3 months time horizon.
Vertex Pharmaceuticals Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Vertex Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vertex Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Vertex Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.09 | 1.76 | 1.33 | 0.11 | 8 Events / Month | 14 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
464.56 | 463.38 | 0.25 |
|
Vertex Pharmaceuticals Hype Timeline
Vertex Pharmaceuticals is at this time traded for 464.56. The entity has historical hype elasticity of -1.33, and average elasticity to hype of competition of -0.11. Vertex is anticipated to decline in value after the next headline, with the price expected to drop to 463.38. The average volatility of media hype impact on the company price is about 11.9%. The price decrease on the next news is expected to be -0.25%, whereas the daily expected return is at this time at -0.09%. The volatility of related hype on Vertex Pharmaceuticals is about 146.3%, with the expected price after the next announcement by competition of 464.45. About 96.0% of the company outstanding shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.22. Vertex Pharmaceuticals recorded a loss per share of 1.91. The entity had not issued any dividends in recent years. The firm had 2:1 split on the 24th of August 2000. Given the investment horizon of 90 days the next anticipated press release will be in about 8 days. Check out Vertex Pharmaceuticals Basic Forecasting Models to cross-verify your projections.Vertex Pharmaceuticals Related Hype Analysis
Having access to credible news sources related to Vertex Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Vertex Pharmaceuticals' future price movements. Getting to know how Vertex Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Vertex Pharmaceuticals may potentially react to the hype associated with one of its peers.
Vertex Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Vertex price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Vertex using various technical indicators. When you analyze Vertex charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Vertex Pharmaceuticals Predictive Indicators
The successful prediction of Vertex Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Vertex Pharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Vertex Pharmaceuticals based on analysis of Vertex Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Vertex Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Vertex Pharmaceuticals's related companies. | 2021 | 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 54.78 | 58.94 | 57.82 | 58.28 | PTB Ratio | 5.6 | 5.32 | 5.96 | 7.46 |
Story Coverage note for Vertex Pharmaceuticals
The number of cover stories for Vertex Pharmaceuticals depends on current market conditions and Vertex Pharmaceuticals' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Vertex Pharmaceuticals is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Vertex Pharmaceuticals' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Vertex Pharmaceuticals Short Properties
Vertex Pharmaceuticals' future price predictability will typically decrease when Vertex Pharmaceuticals' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Vertex Pharmaceuticals often depends not only on the future outlook of the potential Vertex Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Vertex Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 260.5 M | |
| Cash And Short Term Investments | 11.2 B |
Additional Tools for Vertex Stock Analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.